Engineered immune cells take on advanced liver cancer in early trial

NCT ID NCT05155189

First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 10 times

Summary

This early-stage study tests a new treatment called C-CAR031 for people with advanced liver cancer that cannot be removed by surgery. The treatment uses a patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are to check safety and see if the therapy can shrink tumors. The study is currently recruiting 72 participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The first affiliated hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • the First Affiliated Hospital, School of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.